I posted on 2023-8-29 that ginger yellow health products cause liver damage – the French and Australian governments warned that reader Elliot left a message on 2024-2-2 to share an article published on 2024-1-30 The King of Curcumin: a case study in the consequences of large-scale research fraud.
The so-called "King of Huangsu" refers to Dr. Bharat Aggarwal, an Indian-American. He served as a professor at the MD Anderson Cancer Center at the University of Texas from 1989 to 2015. (Note: I almost went to this cancer center as a professor in the same year, but later decided to stay in California)
I searched PubMed, a public medical library with his name and Curcumin, and found 125 articles. I also found 26 of his books on the Amazon Shopping Network, most of which were related to ginger Huangsu. I also found him in 2004, which focused on the development of ginger-based drugs. In addition, he has now withdrawn 30 articles (also a jaw-dropping number), so it seems that he is not overestimated by the title of "King of the Yellow Su" as a net-like name. (Note: There are at least 30 articles published by Aggarwal that are being investigated)
In fact, there are questions about the professor's fraudulent articles. The local Houston Chronicle of the Cancer Center reported on 2-29, 2012. Please see the M.D. Anderson professor under fraud probe (Professor M.D. Anderson's investigation on fraud).
The Houston Chronicle Newspaper published on March 4, 2016, M.D. Anderson scientist, accused of manipulating data, retirees, pointed out that MD Anderson Cancer Center spent four years investigating the professor, which was unusual (usually one and a half years), implying that the cancer center was suspected of being improperly operated (harboring). 【Note: Aggarwal retires before the investigation is about to be completed (2015-12-31), so he enjoys complete retirement benefits. MD Anderson Cancer Center has never published survey results or Aggarwal's retirement. 】
I now translate the focus of the article "King of the Yellow Swallow" as follows:
Bharat B. Aggarwal is an Indian-American biochemist who worked at the MD Anderson Cancer Center from 1989 to 2015. His research focuses on the potential anti-cancer effects and therapeutic applications of herbs and spices. Aggarwal is particularly interested in ginger yellow, a non-toxic compound found in ginger yellow and has long been a major component of the Ayurvedic medical system. From 1994 to 2020, he wrote more than 120 articles about the compound. These articles report that ginger yellow has the potential to treat a variety of diseases, including various cancers, Alzheimer's disease and, more recently, COVID-19. In his 2011 book, “Treat 500 mg of ginger ginger supplements per day to maintain overall health”, Aggarwal suggested “Take 500 mg of ginger supplements per day to maintain overall health”.
MD Anderson Cancer Center initially seemed to fully support Aggarwal's work. The FAQ answer page of their website once suggested visiting customers to buy ginger Huangsu from a company that Aggarwal serves as paid speakers (please refer to "Spice Healer" of "Scientific Americans"). However, in 2012 (after observing the image manipulation behavior proposed by the pseudonym detective Juuichi Jigen), the MD Anderson Cancer Center launched a research fraud investigation into Aggarwal, which ultimately led to the withdrawal of 30 Aggarwal's essays. There are only a few special topics in these studies that address ginger yellow, but most involve similar natural products.
For a single author, the number of retractions is so high. According to the Retraction Watch rankings, only 26 people have written so many of the withdrawn studies. Aggarwal's withdrawn article contains dozens of examples of spliced protein-printed and repeated images, as well as several examples of implanting tumors in mice that are more than ethical. PubPeer commenters noticed that in addition to the 30 retracted articles, many of them have irregular behavior. Aggarwal retired from M.D. Anderson in 2015, but continued to write and attend the meeting.
Ezanthus does not treat any disease well. Although it is safe for human consumption in most forms and shows activity in essentially any off-body assay (by the process called the determination of dryness), there is no strong clinical trial that has been found to be an effective drug. Please refer to Nelson et al. 2017 summary:
"Unfortunately, there is no form of ginger or its closely related analogue (seemingly) with the characteristics required for good candidate drug (chemical stability, high water solubility, effective and selective target activity, high bioavailability, extensive organizational distribution , stable accompliance and low toxicity. However, the extracorporeal interference properties of ginger Huangsu provide many pitfalls that may warn researchers to misjudgment their findings. ”Although ginger Huangsu clearly lacks therapeutic prospects, the number of studies on ginger Huangsu increases every year. More than 2,000 studies involving this compound are published each year. Many of these studies have signs of fraud and discussion manufacturing plants participating. As of 2020, the National Institute of Hygiene (NIH) has spent more than US$150 million to contribute to plans related to ginger. Shortly after Aggarwal began to publish articles about the compound seriously, funds increased significantly in 2007, and the same year he declared ginger Huangsu "Indian solid gold." The surge in
Yellow Huangsu studies has promoted its popularity as a dietary supplement. Grand View Research estimates that by 2020, the global market for ginger yellow as a drug will be about $30 million. Manufacturers are often held accountable by the U.S. Food and Drug Administration for making false claims about the health effects of these supplements.
Yellow Huangsu is a valuable case study that explains how unhindered bullying behavior distorts the entire research field and harms real research. Although there are phenomenal evidence that Aggarwal's research on ginger Huangsu should not be considered reliable, most articles and most research on ginger Huangsu provided by the National Institute of Health still cite Aggarwal's paper. If Aggarwal did not participate in large-scale research fraud, this explosive growth in funds and research seems unlikely to happen.
Recent notes: Shortly after the article was published, Elliot left a message: Similar research standards have deceptions and distorted the phenomenon of the entire research field. It is the most serious in some herbs with national cultural characteristics. South Korean ginseng, Japanese wasabi, Taiwan's angelica, India's ginger, Brazil's Brazilian mushrooms, Central and South American Inca fruit, Russian sea buckthorn, Spain's varietals, etc., all have similar problems with "full structure" research directions. In addition to the "consumption market", "national pride" also shifts the direction of research funds and research fraud. A little personal observation (retraction as a habit of leisure reading) ~
Original text: The King of Huangsu: Big Professors Mass FalsificationResponsible Editor: Gu Zihuan